问题 › 我们不断通过折扣赢得交易 › 医疗服务提供商
基于价值合同中的常规折扣通常是每期成本的证明问题和激励问题，而几乎不是价格问题。 适用于医疗服务提供商的这个问题版本不是通用的。在没有定价所需的每期成本数据的情况下，已接受38,000人的 downside risk — 所以忽略每期成本的答案肯定是错误的。分析必须从支付方组合和面板规模开始，而不是从收入开始。
基于价值合同中的常规折扣通常是每期成本的证明问题和激励问题，而几乎不是价格问题。 适用于医疗服务提供商的这个问题版本不是通用的。在没有定价所需的每期成本数据的情况下，已接受38,000人的 downside risk — 所以忽略每期成本的答案肯定是错误的。分析必须从支付方组合和面板规模开始，而不是从收入开始。
当折扣在支付方谈判中成为常态时，合同费率实际上已重置为折扣水平，而基于价值合同中的基础费率只是装饰。这在38,000名归属生命上的成本不仅仅是边际：它告诉支付方运营商在 downside risk 下会接受什么，而且很难在不失去面板规模的情况下逆转。
原因是一致的。归属生命的每期成本未知或未证明，所以合同谈判中唯一剩下的变量是费率。或者CFO或医疗总监的激励奖励的是达成基于价值的合同而非每位提供商的贡献，在这种情况下折扣正是理性行为。或者支付方组合中的费率自由裁量权不受限制，而不受限制的自由裁量权总是会被使用。
诊断在于分布。如果更深的折扣集中在与主要支付方基于价值合同续约的窗口期，或集中在特定面板或提供商，则原因是围绕每期成本的激励和授权，而非基础费率本身。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 与主要支付方基于价值合同续约前几周，折扣加深
✓ 相似面板之间或CFO与医疗总监在可比归属生命上的折扣水平差异显著
✓ 销售或合同团队要求费率让步，而不是要求归属生命的更好每期成本数据
通常会让情况更糟的做法。 在新的基于价值合同中降低基础费率以匹配近期结果，这会重置锚点，并在两个合同周期内产生新数字的同样折扣。
It is for you if you run or finance a healthcare provider and discounts spike at period end. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Turn 38,000 downside-risk lives into a self-funding 36-month analytics platform via payer co-development.
The leak it closes. Settlement lag (6–9 months) and payer audit adjustments reduced via internal attribution engine
The assumption it rests on. Payer agrees to 5-year exclusivity and 15–25% platform margin split — the engine put the probability at 0.75.
| Investment required | $2.5–3.0M over 18 months |
| Expected return | 7.6–9.1× over three years on $2.5–3.0M investment |
| Revenue, year 1 | $0 (platform build phase) |
| Revenue, year 2 | $6.9–11.4M (first shared-savings settlement) |
| Revenue, year 3 | $13.7–22.8M (full run-rate) |
| Exit criteria | Terminate if payer refuses exclusivity by Month 6 OR if attribution accuracy <80% by Month 18 OR if shared-savings pool < $60M by end of contract year 2 |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 定价与收入优化, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
限制自由裁量权，按边际而非收入支付。折扣是对以收入衡量配额且附带无限价格授权的理性回应。
不是——如果是有意、结构化地交换你想要的东西，比如期限、量或参考。作为谈判结束时的条件反射，它是无谓让出的边际。
在续约时通知并说明理由进行调整，并接受有些客户会离开。替代方案是永久的两级价格，最终会被市场其余部分发现。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית